Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Admilparant + Sildenafil Interaction and PK in Healthy/Japanese Adults
NCT05684289Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Mean placebo-corrected change from baseline in systolic blood pressure up to 16 days, Maximum observed plasma concentration up to 14 days and 2 more. Started Jan 2023; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05684289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684289.